In the first quarter of 2024, Galderma achieved record net sales of $1.071 billion, surpassing the $1 billion mark for the first three months of a year for the first time. Year-on-year net sales grew for the period by 12.4%.
 
Net Sales growth was widespread across product categories and geographies. All product categories grew, with a strong performance in Injectable Aesthetics. 
 
Continued double-digit growth momentum across international markets was fueled by strong performance in major markets. For the U.S., growth accelerated year-on-year and was primarily driven by volume and a favorable product mix.
 
Galderma CEO, Flemming Ørnskov commented:
“We started the year strong, continuing on Galderma’s growth trajectory and celebrating our first days of trading on the SIX Swiss Exchange. This is a testament to our proven integrated dermatology strategy and the focus of our employees globally, each committed to serving our healthcare professionals, consumers, and patients worldwide. With attractive growth across our product categories and geographies, we are confident in our financial outlook for the year.”
 
First-quarter net sales for Galderma’s dermatological skincare segment were $351 million, with year-on-year growth of 8.4% on a constant currency basis.
 
The growth overall was mainly driven by volume and a favorable product mix. Cetaphil in International markets and the Alastin brand grew double digits, offsetting market softness in the U.S. skincare market and the lower U.S. consumption of Cetaphil.
 
Therapeutic Dermatology net sales for the first quarter of 2024 were $209 million, with year-on-year growth of 4.1% on a constant currency basis.
 
Recent new launches were also a strong source of growth, such as Cetaphil’s new ranges including Healthy Renew anti-aging skincare, Sculptra’s launch in Thailand, as well as new product introductions and international expansion for both Alastin and acne brands.

Read Next